查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
多系统萎缩市场：现况分析与预测（2023-2030）
市场调查报告书
商品编码
1346779

多系统萎缩市场：现况分析与预测（2023-2030）

Multiple System Atrophy Market: Current Analysis and Forecast (2023-2030)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 148 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

由于 50-55 岁及以上老年人口不断增加，因此多系统萎缩市场预计在预测期内将以 4% 的复合年增长率增长。 老年人口的增加是全球多系统萎缩市场的驱动因素。 根据世界卫生组织(WHO)预测，到2030年，60岁以上人口的比例将增加至14亿，到2050年将增加至21亿。 中国和印度是世界上人口老化程度最高的国家。

依类型，市场分为帕金森型和小脑型。 到 2022 年，小脑型将占据压倒性的市场。 MSA-C（小脑）被鑑定为小脑性共济失调。 与 MSA-P 相比，MSA-C 的疾病进展较慢，患者存活期相对较长。 到 2020 年，MSA-C 的发生率和盛行率估计为每 10 万人 3.4 至 4.9 例。 因此，小脑亚型盛行率的增加是推动此领域发展的主要因素之一。

依诊断方式分为磁振造影（MRI）、正子断层扫描（PET）、单光子发射断层扫描（SPECT）、倾斜台检查等。 近年来，正子断层扫描（PET）在市场上比其他任何诊断方法都更受欢迎。 PET 诊断可用于监测大脑特定区域的代谢功能。 2023 年，PET 检测在多系统萎缩市场中占据主导地位。 例如，2020年10月，西门子推出了一款名为Biograph Vision Quadra的新型PET扫描器。

依年龄分为儿童、成人、老人。 多系统萎缩在 50 至 55 岁及以上的老年人中变得越来越普遍。 老龄化人口的成长正在推动市场。 预计在预测期内老年人口将显着增加。 根据世界卫生组织的报告，老年人口预计将从 2020 年的 10 亿增加一倍，达到 2050 年的 21 亿。

依最终用途，市场分为医院、门诊手术中心等。 2022年，医院在多系统萎缩市场中占有很大份额。 这是因为多系统萎缩的诊断测试通常在医院进行，因为大多数诊断设备在医院都有。 除此之外，医院数量的增加也推动了这一领域的成长。 例如，根据美国医院协会的数据，截至2022年10月，美国约有6,093家医院，其中包括非营利组织以及州和地方政府营运的社区医院。

为了更了解洁牙片产业的市场介绍，将市场分为北美（美国、加拿大和北美其他地区）、欧洲（德国、英国、法国、西班牙、义大利和其他地区）欧洲）、亚太地区（中国、日本、印度、亚太地区其他地区）以及世界其他国家。 由于神经遗传疾病的增加，2022 年北美将拥有最高的多系统萎缩市场。 预计在预测期内，多系统萎缩将以显着的复合年增长率成长。 根据美国国家神经疾病和中风研究所的数据，这种疾病影响着 15,000 至 50,000 名美国人，无论肤色或种族如何。 此外，该国研发活动的增加也促进了预测期内的市场成长。 预计在预测期内，该地区对多系统萎缩治疗的需求将会增加。 例如，最近（2023年5月）Alterity Therapeutics在美国对其治疗多系统萎缩症的药物ATH434进行了2期试验。

目录

第 1 章市场介绍

  • 市场定义
  • 主要目标
  • 利害关係人
  • 限制

第 2 章研究方法或假设

  • 调查过程
  • 调查方法
  • 受访者简介

第 3 章市场总结

第 4 章执行摘要

第 5 章新型冠状病毒感染（COVID-19）对全球多系统萎缩市场的影响

第 6 章 2020-2030 年全球多系统萎缩市场收入

第 7 章按类型划分的市场洞察

  • 帕金森氏症
  • 小脑

第 8 章诊断市场洞察

  • 磁振造影 (MRI)
  • 正子断层扫描 (PET)
  • 单光子发射电脑断层扫描 (SPECT)
  • 倾斜台测试
  • 其他

第 9 章按年龄划分的市场洞察

  • 儿童
  • 成人
  • 老人

第 10 章最终使用者的市场洞察

  • 医院
  • 门诊手术中心
  • 其他

第 11 章按地区划分的市场洞察

  • 北美
    • 美国
    • 加拿大
    • 其他北美地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区

第 12 章多系统萎缩市场动态

  • 市场促进因素
  • 市场挑战
  • 影响分析

第 13 章多系统萎缩市场机会

第 14 章多系统萎缩市场趋势

第 15 章需求方与供给方分析

  • 需求方分析
  • 供给面分析

第 16 章价值链分析

第 17 章竞争场景

  • 波特五力分析
  • 竞争状况

第 18 章公司简介

  • Biohaven, Ltd.
  • Theravance Biopharma
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Alterity Therapeutics
  • AstraZeneca
  • Biogen
  • Merck & Co., Inc.
  • Neuropore Therapies, Inc.
  • WaveBreak Therapeutics
  • Newron Pharmaceuticals SPA.

第 19 章免责声明

简介目录
Product Code: UMHE212240

Multiple system atrophy is a very rare neurodegenerative disorder of nervous system where nerve cells or brain cells go through a gradual damage. It affects all activities controlled by brain and severely impacts movement, balance and autonomous nervous system. Currently, there is no specific diagnosis test or treatment available in the market for the identification or management of multiple system atrophy. This is one of the major factor driving the market during the forecast period. Several other factors, increase in geriatric population, including government initiatives for research and development activities, promising product pipeline and technological advancements are driving the growth of the market during the forecast period.

The Multiple System Atrophy Market is expected to grow at a strong CAGR of 4% during the forecast period owing to increase in geriatric population, as this disorder is more prevalent in age 50-55 years and above. Rising geriatric population is a propelling factor in Multiple System Atrophy market globally. According to World Health Organization (WHO), share of people aged above 60 will raise to 1.4 billion by 2030 while this share will increase to 2.1 billion by 2050 which would be more than double of the share of geriatric population in year 2020 i.e., 1 billion. China and India are leading in the list of countries with highest geriatric population in the world.

Based on the types, the market is bifurcated into parkinsonian and cerebellar. The cerebellar held dominant share of the market in 2022. MSA-C (cerebellar) is identified with cerebellar ataxia. MSA-C exhibits slower progression of the disease and patients survive relatively a longer life span as compared to MSA-P. The incidence and prevalence of MSA-C is 3.4 to 4.9 cases per 100,000 population as estimated in the year 2020. Thus, the increase in the prevalence of cerebellar subtype is one of the major factor driving the segment growth.

By diagnosis, the market is categorized into magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission computed tomography (SPECT), tilt table test and others. Positron emisssion tomography (PET) has shown more prevalence over the market in recent years than other diagnostic methods. PET diagnostics can be used to monitor metabolic functions in particular part of brain. PET scan dominated Multiple System Atrophy market in year 2023. For instance, in October 2020, Siemens launched a new PET scanner, named Biograph Vision Quadra, with a 106-cm axial PET field of view which facilitates whole-body imaging.

Based on age, the market is differentiated into Pediatric, Adults and Geriatric. Multiple system atrophy has shown prevalence in people aged 50-55 and above. The rising geriatric population has turned out to be a driving factor in the market. The geriatric population is expected to rise considerably in the forecast period. WHO reports suggest that the geriatric population is expected to double (2.1 billion) in year 2050 as compared to the geriatric population (1 billion) in year 2020.

Based on end use, the market is segmented into hospitals, ambulatory surgical centers and others. The hospitals held the significant share in the Multiple System Atrophy Market in 2022. This is due to higher diagnostic tests of multiple system atrophy in hospitals as most diagnostic equipments are available in hospital settings. Apart from this, the growing number of hospitals is also propelling the segmental growth. For instance, according to the American Hospital Association, there were about 6,093 hospitals in the U.S. in October 2022, of which comprises community hospitals run by non-profit organizations as well as by state and local governments.

For a better understanding of the market adoption of the dental clensing tablet industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America has reported highest market share in multiple system atrophy market in the year 2022 owing to rising neurogenetic disorders in the country. Multiple system atrophy is anticipated to grow at a substantial CAGR during the forecast period. According to National Institute of Neurological Disorders and Stroke, it affects significantly 15,000 to 50,000 americans irrespective of colour or racial groups. Further, the rise in research and development activities in the country is also driving the market growth during the forecast period. Over the projection period, this is expected to increase demand for multiple system atrophy treatment in this region. For instance, recently in May,2023, Alterity Therapeutics consucted Phase 2 trials for drug ATH434 against multiple system atrophy in U.S.

Some of the major players operating in the market include: Biohaven, Ltd.; Theravance Biopharma; Sumitomo Dainippon Pharma Co., Ltd.; Alterity Therapeutics; AstraZeneca; Biogen; Merck & Co., Inc.; Neuropore Therapies, Inc.; WaveBreak Therapeutics; Newron Pharmaceuticals SPA.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Multiple System Atrophy Market
  • 2.2. Research Methodology of the Multiple System Atrophy Market
  • 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL MULTIPLE SYSTEM ATROPHY MARKET COVID-19 IMPACT

6 GLOBAL MULTIPLE SYSTEM ATROPHY MARKET REVENUE, 2020-2030F

7 MARKET INSIGHTS BY TYPES

  • 7.1. Parkinsonian
  • 7.2. Cerebellar

8 MARKET INSIGHTS BY DIAGNOSIS

  • 8.1. Magnetic Resonance Imaging (MRI)
  • 8.2. Positron Emission Tomography (PET)
  • 8.3. Single Photon Emission Computed Tomography (SPECT)
  • 8.4. Tilt Table Test
  • 8.5. Others

9 MARKET INSIGHTS BY AGE

  • 9.1. Pediatric
  • 9.2. Adults
  • 9.3. Geriatric

10 MARKET INSIGHTS BY END USER

  • 10.1. Hospitals
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Others

11 MARKET INSIGHTS BY REGION

  • 11.1. North America
    • 11.1.1. United States
    • 11.1.2. Canada
    • 11.1.3. Rest of North America
  • 11.2. Europe
    • 11.2.1. Germany
    • 11.2.2. France
    • 11.2.3. U.K.
    • 11.2.4. Italy
    • 11.2.5. Spain
    • 11.2.6. Rest of Europe
  • 11.3. Asia Pacific
    • 11.3.1. China
    • 11.3.2. Japan
    • 11.3.3. India
    • 11.3.4. Rest of Asia Pacific
  • 11.4. Rest of World

12 MULTIPLE SYSTEM ATROPHY MARKET DYNAMICS

  • 12.1. Market Drivers
  • 12.2. Market Challenges
  • 12.3. Impact Analysis

13 MULTIPLE SYSTEM ATROPHY MARKET OPPORTUNITIES

14 MULTIPLE SYSTEM ATROPHY MARKET TRENDS

15 DEMAND AND SUPPLY-SIDE ANALYSIS

  • 15.1. Demand Side Analysis
  • 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

  • 17.1. Porter's Five Forces Analysis
  • 17.2. Competitive Landscape

18 COMPANY PROFILED

  • 18.1. Biohaven, Ltd.
  • 18.2. Theravance Biopharma
  • 18.3. Sumitomo Dainippon Pharma Co., Ltd.
  • 18.4. Alterity Therapeutics
  • 18.5. AstraZeneca
  • 18.6. Biogen
  • 18.7. Merck & Co., Inc.
  • 18.8. Neuropore Therapies, Inc.
  • 18.9. WaveBreak Therapeutics
  • 18.10. Newron Pharmaceuticals SPA.

19 DISCLAIMER